A Case of a Patient With Type 2 Diabetes in Which Psoriasis Vulgaris Was Improved With Combination Therapy of Biguanide and SGLT2 Inhibitor

Abstract

A 34-year-old man had developed psoriasis vulgaris at 25 years of age and received treatment from a dermatologist, but he discontinued the treatment because the symptoms did not improve. He was diagnosed with type 2 diabetes at 28 years of age and introduced to our hospital. He was administered sulfonylurea and DPP-4 inhibitor but had insufficient glycemic control. As obesity, fatty liver, and insulin resistance were recognized, the addition of a biguanide and SGLT2 inhibitor improved his HbA1c, and, interestingly, marked improvement of his psoriasis was also observed. Because the exacerbation of psoriasis and obesity, fatty liver, and insulin resistance are closely related, treatment that reduces visceral fat and improves fatty liver may also improve psoriasis. We herein report a case of type 2 diabetes in which psoriasis vulgaris was improved by the administration of biguanide and SGLT2 inhibitor.